Thousand Oaks-based biotech giant Amgen said Thursday that it has completed its acquisition of KAI Pharmaceuticals, the South San Francisco-based developer of treatments for treating secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. The deal, which had been announced in April, was worth $315M in cash.